What have been the major advances in CRC care in the past 25 years?

3 Views

07/07/23

Alberto Sobrero, MD, IRCCS Ospedale San Martino IST, Genoa, Italy, discusses the progress that has been made in the past 25 years within the field of colorectal cancer (CRC). The approval of neoadjuvant dostarlimab for patients with rectal cancer has dramatically improved outcomes, and additional immune checkpoint inhibitors have provided much needed treatment options for patients with colon cancer. Liquid biopsies has also made an impact on treatment outcomes, and recent trials such as the Phase III PARADIGM trial (NCT02394795) have been practice-changing in colorectal cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.